Epicardial fat, body mass index, and triglyceride are independent contributors of serum fibroblast growth factor 21 level in obese premenopausal women

Interplay between FGF21 and insulin action in the liver regulates metabolism

(2014) Brice Emanuelli et al.   JOURNAL OF CLINICAL INVESTIGATION

Novel Insights into the Cardio-Protective Effects of FGF21 in Lean and Obese Rat Hearts

(2014) Vanlata Patel et al.   PLoS One

Serum Fibroblast Growth Factor-21 Levels Are Associated With Carotid Atherosclerosis Independent of Established Cardiovascular Risk Factors

(2013) Wing Sun Chow et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease

(2013) Yun Shen et al.   Cardiovascular Diabetology

2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults

(2013) Michael D. Jensen et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Fibroblast Growth Factor 21 as an emerging metabolic regulator: clinical perspectives

(2012) Y. C. Woo et al.   CLINICAL ENDOCRINOLOGY

Serum FGF21 concentration is associated with hypertriglyceridaemia, hyperinsulinaemia and pericardial fat accumulation, independently of obesity, but not with current coronary artery status

(2012) Yenna Lee et al.   CLINICAL ENDOCRINOLOGY

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)

(2012) et al.   EUROPEAN HEART JOURNAL

Serum FGF21 levels are increased in newly diagnosed type 2 diabetes with nonalcoholic fatty liver disease and associated with hsCRP levels independently

(2011) Xuesong Li et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Serum FGF-21 Levels in Type 2 Diabetic Patients

(2011) Xingbo Cheng et al.   ENDOCRINE RESEARCH

Lack of Overt FGF21 Resistance in Two Mouse Models of Obesity and Insulin Resistance

(2011) Clarence Hale et al.   ENDOCRINOLOGY

Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State

(2010) f. M. Fisher et al.   DIABETES

Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease

(2010) Yusuf Yilmaz et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Serum fibroblast growth factor–21 concentration is associated with residual renal function and insulin resistance in end-stage renal disease patients receiving long-term peritoneal dialysis

(2010) Seung Hyeok Han et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Relation between fibroblast growth factor–21, adiposity, metabolism, and weight reduction

(2010) Knut Mai et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Serum Levels of FGF-21 Are Increased in Coronary Heart Disease Patients and Are Independently Associated with Adverse Lipid Profile

(2010) Zhuofeng Lin et al.   PLoS One

Serum Fibroblast Growth Factor 21 Is Associated with Adverse Lipid Profiles and γ-Glutamyltransferase But Not Insulin Sensitivity in Chinese Subjects

(2009) Huating Li et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Echocardiographic Epicardial Fat: A Review of Research and Clinical Applications

(2009) Gianluca Iacobellis et al.   JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY

Serum FGF21 Levels Are Increased in Obesity and Are Independently Associated With the Metabolic Syndrome in Humans

(2008) X. Zhang et al.   DIABETES

Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice

(2008) J. Xu et al.   DIABETES

Fibroblast Growth Factor 21 Corrects Obesity in Mice

(2008) Tamer Coskun et al.   ENDOCRINOLOGY

FGF21 attenuates lipolysis in human adipocytes - A possible link to improved insulin sensitivity

(2008) Peter Arner et al.   FEBS LETTERS